



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/19, C07K 14/52, C12P 21/02, C07K 14/715, 16/28, A61K 38/19, 38/17, G01N 33/68, A61K 39/395		A1	(11) International Publication Number: WO 95/07985 (43) International Publication Date: 23 March 1995 (23.03.95)
(21) International Application Number: PCT/GB94/02006 (22) International Filing Date: 14 September 1994 (14.09.94) (30) Priority Data: 9318984.3 14 September 1993 (14.09.93) GB 9408602.2 29 April 1994 (29.04.94) GB (71) Applicants (for all designated States except US): NATIONAL HEART & LUNG INSTITUTE [GB/GB]; Dovehouse Street, London SW3 6LY (GB). LUDWIG INSTITUTE FOR CANCER RESEARCH [GB/GB]; Hedges House, 153-155 Regent Street, London W1R 7FD (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): WILLIAMS, Timothy, John [GB/GB]; National Heart & Lung Institute, Dovehouse Street, London SW3 6LY (GB). JOSE, Peter, John [GB/GB]; National Heart & Lung Institute, Dovehouse Street, London SW3 6LY (GB). GRIFFITHS-JOHNSON, David, A. [GB/GB]; National Heart & Lung Institute, Dovehouse Street, London SW3 6LY (GB). HSUAN, John, Justin [GB/GB]; Ludwig Institute for Cancer Research, Hedges House, 153-155 Regent Street, London W1R 7FD (GB).		(74) Agents: SILVESTON, Judith et al.; Abel & Imray, Northumberland House, 303-306 High Holborn, London WC1V 7LH (GB). (81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	

(54) Title: EOTAXIN: EOSINOPHIL CHEMOTACTIC CYTOKINE

(57) Abstract

A chemoattractant protein called "eotaxin" is capable of attracting eosinophils and of inducing eosinophil accumulation and/or activation in vitro and in vivo. Various types of agents that inhibit or otherwise hinder the production, release or activity of eotaxin may be used therapeutically in the treatment of asthma and other inflammatory diseases.

